Featured Research

from universities, journals, and other organizations

Promising new option for first line of attack in lymphoma

Date:
February 25, 2014
Source:
Manchester University
Summary:
Follicular lymphoma is a type of non-Hodgkin’s lymphoma -– a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage. Recent improvements in treatment have included the use of antibodies to specifically target the tumor cells and to stimulate the patient’s own immune system to attack their tumor. The use of such antibodies has improved treatment response, but unfortunately most patients still relapse Radioimmunotherapy -- where a radioactive substance is attached to the antibody -- has been shown to be successful in treating patients who had previously relapsed.

A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.

Related Articles


Follicular lymphoma is a type of non-Hodgkin's lymphoma- a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

Recent improvements in treatment have included the use of antibodies to specifically target the tumor cells and to stimulate the patient's own immune system to attack their tumor.

The use of such antibodies has improved treatment response, but unfortunately most patients still relapse.

Radioimmunotherapy -- where a radioactive substance is attached to the antibody -- has been shown to be successful in treating patients who had previously relapsed.

Now a team involving researchers from The University of Manchester -- part of the Manchester Cancer Research Centre -- has investigated the use of radioimmunotherapy treatment in newly diagnosed patients.

The study published in the Journal of Clinical Oncology, looked at the effect of delivering the treatment in two fractions or doses -- this approach is thought to improve the penetration of the drug within larger tumors and also helps reduce the side effects associated with a full dose treatment.

Professor Tim Illidge, who led the research, said: "This was the first study to look at giving two fractions of radioimmunotherapy as an initial treatment in follicular lymphoma. We wanted to assess its safety and effectiveness in a group of high-risk patients who conventionally have done less well."

The researchers found that that their treatment plan was feasible and safe, with very few side effects.

"We saw a high overall response rate, of 94.4%, and 50 of the 72 (69.4%) patients treated in the study achieved complete response -- meaning their symptoms disappeared. These results are encouraging, but we need further studies in larger numbers of patients to fully compare this treatment to the standard treatment of 6-8 cycles of chemotherapy," added Professor Illidge.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. M. Illidge, S. Mayes, R. Pettengell, A. T. Bates, M. Bayne, J. A. Radford, W. D. J. Ryder, S. Le Gouill, F. Jardin, J. Tipping, M. Zivanovic, F. Kraeber-Bodere, M. Bardies, C. Bodet-Milin, E. Malek, D. Huglo, F. Morschhauser. Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology, 2013; 32 (3): 212 DOI: 10.1200/JCO.2013.50.3110

Cite This Page:

Manchester University. "Promising new option for first line of attack in lymphoma." ScienceDaily. ScienceDaily, 25 February 2014. <www.sciencedaily.com/releases/2014/02/140225101250.htm>.
Manchester University. (2014, February 25). Promising new option for first line of attack in lymphoma. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2014/02/140225101250.htm
Manchester University. "Promising new option for first line of attack in lymphoma." ScienceDaily. www.sciencedaily.com/releases/2014/02/140225101250.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins